Cardiovascular disease (CVD) remains the leading cause of death worldwide, accounting for nearly 18 million deaths annually. As the burden of heart disease, stroke, and related conditions continues to rise, the demand for robust Health Economics and Outcomes Research (HEOR) has never been greater. Pharmaceutical companies, medical device manufacturers, and health systems increasingly rely on specialized HEOR firms to generate real-world evidence, cost-effectiveness models, and outcomes data that inform market access, reimbursement, and clinical decisions.

Whether you're a biopharma company seeking payer approval for a novel anticoagulant or a health system evaluating the value of a new lipid-lowering therapy, partnering with the right HEOR firm is critical. Below, we highlight the top 10 HEOR companies for cardiovascular disease studies.

1. DelveInsight

DelveInsight stands out as a premier HEOR powerhouse, offering end-to-end health economics and outcomes research services tailored specifically to cardiovascular and other high-burden therapeutic areas. Their cardiovascular HEOR capabilities span cost-of-illness analyses, budget impact models, patient-reported outcomes (PRO), systematic literature reviews (SLR), and robust health technology assessment (HTA) dossier preparation. With a team of seasoned health economists, epidemiologists, and data scientists, DelveInsight delivers actionable insights that support reimbursement submissions, formulary negotiations, and value-based care strategies. Their deep cardiovascular expertise — covering conditions from heart failure and atrial fibrillation to acute coronary syndromes — makes them the go-to partner for companies seeking evidence-based differentiation in competitive markets.

Key Services: Cost-effectiveness analysis, budget impact modeling, RWE studies, HTA submissions, SLR, PRO research.

2. IQVIA

IQVIA is a global leader in healthcare data and analytics, offering comprehensive HEOR services backed by one of the world's largest real-world data (RWD) repositories. In cardiovascular research, IQVIA excels at generating retrospective database studies, comparative effectiveness research, and patient journey analyses across millions of patients.

3. Evidera

A PPD company, Evidera specializes in evidence synthesis, economic modeling, and outcomes research. Their cardiovascular practice is well-regarded for developing complex Markov and discrete event simulation models used in global HTA submissions.

4. Parexel

Parexel's HEOR and market access division supports cardiovascular drug developers from early clinical planning through post-launch outcomes studies. Their integrated approach aligns clinical trial endpoints with payer-relevant outcomes from the outset.

5. Covance (Labcorp Drug Development)

Covance brings broad HEOR expertise to cardiovascular trials, including patient registries, health utility measurement, and integrated evidence planning to streamline global market access for cardiovascular therapeutics.

6. Medicus Economics

Medicus Economics is a boutique HEOR consultancy known for high-quality health economic modeling in cardiovascular and metabolic diseases. They are recognized for transparent, HTA-ready models that withstand rigorous scrutiny from agencies like NICE and ICER.

7. Symmetron

Symmetron provides integrated evidence strategies and HEOR support, with experience in cardiovascular outcomes trials (CVOTs) and post-market evidence generation to demonstrate real-world value to global payers.

8. RTI Health Solutions

RTI Health Solutions offers a full spectrum of HEOR services including patient-centered outcomes research, PRO instrument development, and systematic reviews. Their cardiovascular portfolio includes landmark studies supporting major lipid-lowering and antihypertensive therapies.

9. Xcenda

An AmerisourceBergen consulting group, Xcenda delivers market access and HEOR solutions with strong payer communication capabilities. Their cardiovascular work spans from pre-launch value dossier development to post-launch real-world evidence generation.

10. Lumanity

Lumanity (formerly Mtech Access and other integrated firms) brings together evidence, access, and commercialization expertise. In cardiovascular disease, they support HTA submissions, formulary negotiations, and integrated evidence frameworks across the US and European markets.

Conclusion

Selecting the right HEOR partner for cardiovascular disease research can mean the difference between a successful market access strategy and costly delays. Each firm on this list brings unique strengths — but for comprehensive, cardiovascular-focused HEOR that covers the full evidence lifecycle, DelveInsight consistently delivers superior value. From model development to HTA dossiers and real-world evidence, they are trusted by leading biopharma and device companies worldwide.

To learn more about how expert HEOR Analysis Firms can accelerate your cardiovascular market access journey, explore DelveInsight's specialized HEOR services today.